Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Therapeutic Area Director
+11 year(s) experience
He stays abreast of market developments, generating and curating data sources, and distilling these into reports that enable clients to gain a competitive edge.
Since joining Pharma Intelligence in 2010, Daniel has tracked and forecast all the leading neurology, psychiatry, and pain drug markets. He is particularly interested in the shifting landscape of the multiple sclerosis market well as the implications of trial failures – alongside the successes in Alzheimer's disease R&D.
He has helped expand research and insight on rare diseases , including established orphan drug markets as well as as emerging opportunities. He also attends international medical conferences and enjoys collaborating with colleagues at Scrip.
Daniel has a First Class degree in Natural Sciences from the University of Bath.
Trialtrove
Disruption to clinical trials was a well-documented side effect of the COVID-19 pandemic, with trial sponsors and clinical sites dramatically scaling back activities in line with increased hospital burden, lockdown measures, and reduced patient mobility.
Topic Coronavirus Clinical Trials Clinical Trials Blog BioPharmaceutical
Datamonitor Healthcare
Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination.
In Vivo
Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination. Consequently, industry perception scores have ticked upwards sharply, albeit from a low base.
Biomedtracker, Datamonitor Healthcare
With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target
Topic BioPharmaceutical Drug Review
Biomedtracker
Using M&A activity as a barometer for the overall health of the biopharma industry, we explore biopharma’s biggest deals of the past decade and examine what they may presage for the year to come. Dive into key insights on trends, M&A drivers, companies to watch, and more.
Topic M A
In Vivo, Citeline
“Pipeline-in-a-pill” has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.
Topic BioPharmaceutical Drug Pricing Drug Review Drug Development Landscape
Datamonitor Healthcare, Scrip, Trialtrove, In Vivo, Pharma C...
The tumor-agnostic developer’s toolkit
Scrip
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.
Datamonitor Healthcare, Biomedtracker, Pharmaprojects, Scrip...
As the biopharma industry concludes its annual pilgrimage to San Francisco for the JP Morgan investor conference, much of the talk around town inevitably was about gene therapies.
Topic Cell and gene therapy
Datamonitor Healthcare, Pharmaprojects, Biomedtracker
In previous years, delegates at the American Society for Clinical Oncology (ASCO) annual meeting had been treated to exciting clinical data from anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies such as Kymriah (tisagenlecleucel; Novartis), Yescarta (axicabtagene ciloleucel; Gilead), and various pipeline assets in advanced hematologic malignancies.
Topic Cancer Cell and gene therapy
Datamonitor Healthcare
In April, immuno-oncology (IO) celebrated its ninth birthday, following the approval of Provenge, the first drug that harnesses the body’s immune system to fight cancer, in April 2010. Since this landmark event, it has been a tremendous decade for the field, with IO becoming part of the standard-of-care in a range of treatment settings and the Nobel Prize being awarded for the discovery of immune checkpoint inhibition. It is the checkpoint inhibitor drug classes that are leading the IO revolution and will act as a foundation for the next decade of oncology research. This article reviews the childhood years of IO and predicts what the future may hold as it reaches double digits and matures through adolescence.
Topic Cancer
Strategic Transactions
PharmAI – industry is smartening up to the potential of artificial intelligence
Datamonitor Healthcare
New clinical data and a deepening treatment algorithm will drive market growth
Topic Research wire
Datamonitor Healthcare
Alkermes has announced the failure of two of its pivotal trials for its novel opioid-targeting antidepressant ALKS 5461 (buprenorphine/samidorphan), yet is emboldened by an efficacy signal
Topic Alkermes
Datamonitor Healthcare
Alkermes has announced the failure of two of its pivotal trials for its novel opioid-targeting antidepressant ALKS 5461
Scrip
09 Mar 2021
In Vivo
23 Nov 2020
In Vivo
17 Nov 2020
In Vivo
15 Jun 2020
In Vivo
11 May 2020
In Vivo
03 Feb 2020
Scrip
10 Sep 2019
In Vivo
03 Jun 2019
Scrip
30 May 2019
In Vivo
15 Apr 2019
Scrip
26 Jan 2016
Scrip
13 Oct 2015
